Ratings Assigned to AmeriCredit Automobile Receivables Trust 2000-A Feb 00

  • ID: 1802444
  • February 2000
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's CreditWire) Feb. 24, 2000--Standard & Poor's assigned its ratings to AmeriCredit Automobile Receivables Trust 2000-A's US$1.3 billion asset-backed notes (see list). The ratings on the fixed-rate class A-2, A-3, and A-4 notes are based on the insurance policy provided by Financial Security Assurance Inc. (FSA; triple-'A' insurer financial strength rating). Under this policy, FSA unconditionally and irrevocably guarantees payment of scheduled principal and interest. While FSA is also insuring the class A-1 fixed-rate notes, Standard & Poor's rating on these notes is not based on the policy, but rather on internal credit support and conservative cash flow projections. Standard & Poor's has determined that the underlying transaction risk assumed by FSA is consistent with an...

Companies mentioned in this report are: General Motors Financial Co. Inc.
Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

General Motors Financial Co. Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.